Apply to areas with good circulation like the upper arms or abdomen
Gastrointestinal issues are usually strongest in first-time users, or when people step up to a larger dosage, but they usually dissipate over time
A 2019 network meta-analysis of 233 trials (n = 147,710) reported elevated risks of dizziness (odds ratios [ORs] 1.92, 1.57, 1.40) and headache (ORs 1.34, 1.41, 1.18) with GLP-1 RAs versus insulin, thiazolidinediones, and placebo 40
It is important to understand that an MDL is not a class action
So Im still getting the perspective of those in North America and Japan and other places
Lieberman DE, Aslan DH, Heymsfield SB